NCR3 and neoplasm: Here, Becker and colleagues discovered and engineered novel NKp30-based natural killer cell engagers that do not compete with their natural ligand B7-H6, thereby allowing and enhancing the natural recognition of B7-H6+ tumor cells by natural killer cells.